Company: EUDAW
Filing Date: 2025-12-04
Form Type: 424B5
Source: 0001493152-25-026224
Chunk: 24

Company: EUDA Health Holdings Ltd
Filing Date: 2025-12-04
Form: 424B5
Chunk 24
---
 related to the prevailing market price, at varying prices determined at the time of sale, or at negotiated prices. We will not receive any of the proceeds from the offering by the Investor of any such Ordinary Shares. If any such Ordinary Shares are sold through underwriters or broker-dealers, we will not be responsible for underwriting discounts or commissions or agents’ commissions.

The Investor may use any one or more of the following methods when disposing of any such Ordinary Shares or interests therein:

1. on any other national securities exchange or U.S. inter-dealer system of a registered national securities association on which our ordinary shares may be listed or quoted at the time of sale;

2. ordinary brokerage transactions and transactions in which the broker-dealer solicits purchasers;

3. one or more underwritten offerings;

| S-16 |

4. block trades in which the broker-dealer will attempt to sell the shares as agent, but may position and resell a portion of the block as principal to facilitate the transaction;

5. purchases by a broker-dealer as principal and resale by the broker-dealer for its account;

6. an exchange distribution in accordance with the rules of the applicable exchange;

7. privately negotiated transactions;

8. short sales effected after the date the registration statement of which this prospectus is a part is declared effective by the SEC;

9. through the writing or settlement of options or other hedging transactions, whether through an options exchange or otherwise; and

10. in any combination of the above or by any other legally available means.

The Investor may, from time to time, pledge or grant a security interest in some of the Ordinary Shares issued upon exercise of the Warrant and, if the Investor defaults in the performance of its secured obligations, the pledgees or secured parties may offer and sell such Ordinary Shares, from time to time, under this prospectus, or under an amendment or supplement to this prospectus to include the pledgee, transferee or other successors in interest as selling stockholders under this prospectus. In connection with the sale of any such Ordinary Shares or interests therein, the Investor may enter into hedging transactions with broker-dealers or other financial institutions, which may in turn engage in short sales of our ordinary shares in the course of hedging the positions they assume. The Investor may also sell our ordinary shares short and deliver any such Ordinary Shares to close out their short positions.

The Investor also may resell the Ordinary Shares issued upon exercise of the Warrant in open market transactions in reliance upon Rule 144 under